Fueling autoimmunity: Type i interferon in autoimmune diseases

Expert Review of Clinical Immunology

Volumn 9, Issue 3, 2013, Pages 201-210

  Di Domizio, Jeremy ^a   Cao, Wei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

anti interferon therapy; autoimmune disease; innate immune activation; interferon induction; lupus model; nucleic acids; plasmacytoid dendritic cells; systemic lupus erythematosus; Toll like receptor; type I interferon

Indexed keywords

AGS 009; ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; AUTOANTIBODY; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BELIMUMAB; BETA INTERFERON; BETA INTERFERON RECEPTOR; CPG 52364; DOUBLE STRANDED DNA ANTIBODY; DV 1179; EXODEOXYRIBONUCLEASE III; FC RECEPTOR IIA; GAMMA INTERFERON; IMMUNOMODULATING AGENT; IMO 3100; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYELOID DIFFERENTIATION FACTOR 88; RECOMBINANT INTERFERON; RIBONUCLEOPROTEIN; RONTALIZUMAB; SIFALIMUMAB; STAT PROTEIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AICARDI GOUTIERES SYNDROME; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL POPULATION; DENDRITIC CELL; DERMATOMYOSITIS; DISEASE COURSE; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG TARGETING; EXPERIMENTAL MODEL; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HUMAN; IMMUNIZATION; INNATE IMMUNITY; LEUKOCYTE; LUPUS LIKE SYNDROME; LUPUS VULGARIS; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; VIRUS INFECTION;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84874598307     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.106     Document Type: Review

References (104)

1. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (α/β) in immunity and autoimmunity. Annu. Rev. Immunol. 23, 307-336 (2005).
2. Yan N, Chen ZJ. Intrinsic antiviral immunity. Nat. Immunol. 13(3), 214-222 (2012).
3. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 301(1), 5-8 (1979).
4. Tsokos GC. Systemic lupus erythematosus. N. Engl. J. Med. 365(22), 2110-2121 (2011).
5. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25(3), 383-392 (2006).
6. Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 17(5), 394-399 (2008).
7. Chaussabel D, Quinn C, Shen J et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29(1), 150-164 (2008).
8. Lugar PL, Love C, Grammer AC, Dave SS, Lipsky PE. Molecular characterization of circulating plasma cells in patients with active systemic lupus erythematosus. PLoS ONE 7(9), e44362 (2012).
9. Ohl K, Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J. Biomed. Biotechnol. 2011, 432595 (2011).
10. Postal M, Sinicato NA, Peliçari KO, Marini R, Lavras Costallat LT, Appenzeller S. Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus. Clinics (Sao Paulo) 67(2), 157-162 (2012).
11. Peterson KS, Huang JF, Zhu J et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J. Clin. Invest. 113(12), 1722-1733 (2004).
12. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8(8), 594-606 (2008).
13. Gottenberg JE, Cagnard N, Lucchesi C et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc. Natl Acad. Sci. USA 103(8), 2770-2775 (2006).
14. Eloranta ML, Franck-Larsson K, Lövgren T et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann. Rheum. Dis. 69(7), 1396-1402 (2010).
15. Baechler EC, Bilgic H, Reed AM. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res. Ther. 13(6), 249 (2011).
16. Higgs BW, Liu Z, White B et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann. Rheum. Dis. 70(11), 2029-2036 (2011).
17. Yanick JC. Type I interferonopathies: a novel set of inborn errors of immunity. Ann. N. Y. Acad. Sci. 1238, 91-98 (2011).
18. Crow YJ, Hayward BE, Parmar R et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi- Goutières syndrome at the AGS1 locus. Nat. Genet. 38(8), 917-920 (2006).
19. Lee-Kirsch MA, Gong M, Chowdhury D et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet. 39(9), 1065-1067 (2007).
20. Briggs TA, Rice GI, Daly S et al. Tartrateresistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat. Genet. 43(2), 127-131 (2011).
21. Lausch E, Janecke A, Bros M et al. Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat. Genet. 43(2), 132-137 (2011).
22. Berry MP, Graham CM, McNab FW et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466(7309), 973-977 (2010).
23. Swiecki M, Gilfillan S, Vermi W, Wang Y, Colonna M. Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell accrual. Immunity 33(6), 955-966 (2010).
24. Cervantes-Barragan L, Lewis KL, Firner S et al. Plasmacytoid dendritic cells control T-cell response to chronic viral infection. Proc. Natl Acad. Sci. USA 109(8), 3012-3017 (2012).
25. Goodnow CC. Immunology. Discriminating microbe from self suffers a double toll. Science 312(5780), 1606-1608 (2006).
26. Cho JH, Gregersen PK. Genomics and the multifactorial nature of human autoimmune disease. N. Engl. J. Med. 365(17), 1612-1623 (2011).
27. Niewold TB. Interferon α as a primary pathogenic factor in human lupus. J. Interferon Cytokine Res. 31(12), 887-892 (2011).
28. Shen N, Fu Q, Deng Y et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 107(36), 15838-15843 (2010).
29. Salloum R, Niewold TB. Interferon regulatory factors in human lupus pathogenesis. Transl. Res. 157(6), 326-331 (2011).
30. Hagberg N, Berggren O, Leonard D et al. IFN-a production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes is promoted by NK cells via MIP-1b and LFA-1. J. Immunol. 186(9), 5085-5094 (2011).
31. Eloranta ML, Lövgren T, Finke D et al. Regulation of the interferon-α production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 60(8), 2418-2427 (2009).
32. Santer DM, Wiedeman AE, Teal TH, Ghosh P, Elkon KB. Plasmacytoid dendritic cells and C1q differentially regulate inflammatory gene induction by lupus immune complexes. J. Immunol. 188(2), 902-915 (2012).
33. Santer DM, Hall BE, George TC et al. C1q deficiency leads to the defective suppression of IFN-α in response to nucleoprotein containing immune complexes. J. Immunol. 185(8), 4738-4749 (2010).
34. Wenzel J, Tüting T. An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in "interface dermatitis". J. Invest. Dermatol. 128(10), 2392-2402 (2008).
35. Lande R, Gregorio J, Facchinetti V et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449(7162), 564-569 (2007).
36. Shrestha S, Wershil B, Sarwark JF, Niewold TB, Philipp T, Pachman LM. Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum. 62(9), 2813-2822 (2010).
37. Denny MF, Yalavarthi S, Zhao W et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J. Immunol. 184(6), 3284-3297 (2010).
38. Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil function: from mechanisms to disease. Annu. Rev. Immunol. 30, 459-489 (2012).
39. Lande R, Ganguly D, Facchinetti V et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 3(73), 73ra19 (2011).
40. Garcia-Romo GS, Caielli S, Vega B et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3(73), 73ra20 (2011).
41. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29, 139-162 (2011).
42. Tian J, Avalos AM, Mao SY et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8(5), 487-496 (2007).
43. Popovic PJ, DeMarco R, Lotze MT et al. High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J. Immunol. 177(12), 8701-8707 (2006).
44. Urbonaviciute V, Fürnrohr BG, Meister S et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205(13), 3007-3018 (2008).
45. Sideras K, Gertz MA. Amyloidosis. Adv. Clin. Chem. 47, 1-44 (2009).
46. Schnabel J. Protein folding: the dark side of proteins. Nature 464(7290), 828-829 (2010).
47. Fowler DM, Koulov AV, Balch WE, Kelly JW. Functional amyloid-from bacteria to humans. Trends Biochem. Sci. 32(5), 217-224 (2007).
48. Badtke MP, Hammer ND, Chapman MR. Functional amyloids signal their arrival. Sci. Signal. 2(80), pe43 (2009).
49. Maji SK, Perrin MH, Sawaya MR et al. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science 325(5938), 328-332 (2009).
50. Jiménez JS. Protein-DNA interaction at the origin of neurological diseases: a hypothesis. J. Alzheimers Dis. 22(2), 375-391 (2010).
51. Di Domizio J, Zhang R, Stagg LJ et al. Binding with nucleic acids or glycosaminoglycans converts soluble protein oligomers to amyloid. J. Biol. Chem. 287(1), 736-747 (2012).
52. Chen M, Wang YH, Wang Y et al. Dendritic cell apoptosis in the maintenance of immune tolerance. Science 311(5764), 1160-1164 (2006).
53. Kim SJ, Zou YR, Goldstein J, Reizis B, Diamond B. Tolerogenic function of Blimp-1 in dendritic cells. J. Exp. Med. 208(11), 2193-2199 (2011).
54. Kool M, van Loo G, Waelput W et al. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity 35(1), 82-96 (2011).
55. Joo H, Coquery C, Xue Y et al. Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation. J. Exp. Med. 209(7), 1335-1348 (2012).
56. Lee PY, Li Y, Kumagai Y et al. Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. Am. J. Pathol. 175(5), 2023-2033 (2009).
57. Spadaro F, Lapenta C, Donati S et al. IFN-a enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 119(6), 1407-1417 (2012).
58. Simmons DP, Wearsch PA, Canaday DH et al. Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. J. Immunol. 188(7), 3116-3126 (2012).
59. Longhi MP, Trumpfheller C, Idoyaga J et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206(7), 1589-1602 (2009).
60. Cucak H, Yrlid U, Reizis B, Kalinke U, Johansson-Lindbom B. Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity 31(3), 491-501 (2009).
61. Tough DF. Modulation of T-cell function by type I interferon. Immunol. Cell Biol. 90(5), 492-497 (2012).
62. Mathian A, Gallegos M, Pascual V, Banchereau J, Koutouzov S. Interferon-α induces unabated production of short-lived plasma cells in pre-autoimmune lupusprone (NZB×NZW)F1 mice but not in BALB/c mice. Eur. J. Immunol. 41(3), 863-872 (2011).
63. Mackay F, Schneider P. Cracking the BAFF code. Nat. Rev. Immunol. 9(7), 491-502 (2009).
64. Rönnblom L, Alm GV, Eloranta ML. Type I interferon and lupus. Curr. Opin. Rheumatol. 21(5), 471-477 (2009).
65. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest. 118(5), 1680-1690 (2008).
66. Moschen AR, Geiger S, Krehan I, Kaser A, Tilg H. Interferon-α controls IL-17 expression in vitro and in vivo. Immunobiology 213(9-10), 779-787 (2008).
67. Taylor KE, Chung SA, Graham RR et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet. 7(2), e1001311 (2011).
68. Morel L. Genetics of SLE: evidence from mouse models. Nat. Rev. Rheumatol. 6(6), 348-357 (2010).
69. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv. Immunol. 37, 269-390 (1985).
70. Fairhurst AM, Mathian A, Connolly JE et al. Systemic IFN-α drives kidney nephritis in B6.Sle123 mice. Eur. J. Immunol. 38(7), 1948-1960 (2008).
71. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 37(12), 3582-3586 (2007).
72. Santiago-Raber ML, Baccala R, Haraldsson KM et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197(6), 777-788 (2003).
73. Guiducci C, Tripodo C, Gong M et al. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J. Exp. Med. 207(13), 2931-2942 (2010).
74. Hohensinner PJ, Goronzy JJ, Weyand CM. Telomere dysfunction, autoimmunity and aging. Aging Dis. 2(6), 524-537 (2011).
75. Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin. Rev. Allergy Immunol. 42(1), 102-111 (2012).
76. Pathak S, Mohan C. Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models. Arthritis Res. Ther. 13(5), 241 (2011).
77. Pisetsky DS. Immune activation by bacterial DNA: a new genetic code. Immunity 5(4), 303-310 (1996).
78. Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J. Exp. Med. 188(2), 387-392 (1998).
79. Di Domizio J, Dorta-Estremera S, Gagea M et al. Nucleic acid-containing amyloid fibrils potently induce type I interferon and stimulate systemic autoimmunity. Proc. Natl Acad. Sci. USA 109(36), 14550-14555 (2012).
80. Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 30(9), 455-464 (2009).
81. Lee PY, Weinstein JS, Nacionales DC et al. A novel type I IFN-producing cell subset in murine lupus. J. Immunol. 180(7), 5101-5108 (2008).
82. Lee PY, Kumagai Y, Li Y et al. TLR7- dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J. Exp. Med. 205(13), 2995-3006 (2008).
83. Ho FC, Fu KH. A new model of AA-amyloidosis induced by oral pristane in BALB/c mice. Br. J. Exp. Pathol. 68(3), 413-420 (1987).
84. Cheung YH, Loh C, Pau E, Kim J, Wither J. Insights into the genetic basis and immunopathogenesis of systemic lupus erythematosus from the study of mouse models. Semin. Immunol. 21(6), 372-382 (2009).
85. Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat. Rev. Immunol. 12(7), 479-491 (2012).
86. Gall A, Treuting P, Elkon KB et al. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 36(1), 120-131 (2012).
87. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134(4), 587-598 (2008).
88. Ahn J, Gutman D, Saijo S, Barber GN. STING manifests self DNA-dependent inflammatory disease. Proc. Natl Acad. Sci. USA 109(47), 19386-19391 (2012).
89. Hron JD, Peng SL. Type I IFN protects against murine lupus. J. Immunol. 173(3), 2134-2142 (2004).
90. Liu J, Karypis G, Hippen KL et al. Genomic view of systemic autoimmunity in MRLlpr mice. Genes Immun. 7(2), 156-168 (2006).
91. Sangaletti S, Tripodo C, Chiodoni C et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood 120(15), 3007-3018 (2012).
92. Knight JS, Kaplan MJ. Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis. Curr. Opin. Rheumatol. 24(5), 441-450 (2012).
93. Campbell AM, Kashgarian M, Shlomchik MJ. NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci. Transl. Med. 4(157), 157ra141 (2012).
94. Guiducci C, Gong M, Xu Z et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465(7300), 937-941 (2010).
95. Gregersen JW, Jayne DR. B-cell depletion in the treatment of lupus nephritis. Nat. Rev. Nephrol. 8(9), 505-514 (2012).
96. Pisetsky DS, Grammer AC, Ning TC, Lipsky PE. Are autoantibodies the targets of B-cell-directed therapy? Nat. Rev. Rheumatol. 7(9), 551-556 (2011).
97. Merrill JT, Wallace DJ, Petri M et al.; Lupus Interferon Skin Activity (LISA) Study Investigators. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a Phase I, multicentre, double-blind randomised study. Ann. Rheum. Dis. 70(11), 1905-1913 (2011).
98. Morimoto AM, Flesher DT, Yang J et al. Association of endogenous antiinterferon- α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 63(8), 2407-2415 (2011).
99. Houssiau FA, Rashkov R, Hachulla E et al. Active immunization against IFNα with IFN-kinoid in SLE patients is safe, immunogenic and induces down-regulation of IFN-mediated genes. Arthritis Rheum. 63, S963 (2011).
100. Browne SK, Holland SM. Immunodeficiency secondary to anticytokine autoantibodies. Curr. Opin. Allergy Clin. Immunol. 10(6), 534-541 (2010).
101. González-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12(2), 125-135 (2012).
102. Crow MK. Type I interferon in organtargeted autoimmune and inflammatory diseases. Arthritis Res. Ther. 12 Suppl. 1, S5 (2010).
103. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-α in autoimmune diseases. Proc. Natl Acad. Sci. USA 102(9), 3372-3377 (2005).
104. Crampton SP, Deane JA, Feigenbaum L, Bolland S. Ifih1 gene dose effect reveals MDA5-mediated chronic type I IFN gene signature, viral resistance, and accelerated autoimmunity. J. Immunol. 188(3), 1451-1459 (2012).